Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


June 18-20, 2019
Park Central Hotel,
San Francisco, CA


Get unparalleled coverage of the discovery, engineering, and development of novel protein therapeutics and bioconjugates.

Accelerate promising new molecules into differentiated products

Next Generation Bioconjugates
  • Tackle bioconjugations beyond cytotoxins: What are the next generation modalities?
  • Get top tips on novel conjugation techniques to improve selectivity, yield, and stability
  • Delve into innovative linkers and higher drug payloads used to improve efficacy and target selectivity
Creative Engineering & Discovery Technologies
  • Get informed on where next generation therapeutics can be used: What are the hot new targets?
  • Uncover creative engineering and design approaches for next generation protein therapeutics: Bi and multi specifics, Bispecific T cell engagers, Non-Antibody Scaffolds, Target Immunotherapies
  • Stay on top of new technologies to improve discovery, design, and developability assessment
Clinical Translation, Regulatory Requirements & Delivery
  • Discover how next generation protein therapeutic are translating from discovery into the clinic: What lessons have been learned to advance drug design?
  • Hear directly from the FDA on regulatory expectations for novel therapeutics and bioconjugates
  • Achieve delivery into cells and across the blood-brain barrier

Exclusive Whitepaper Downloads

Innovative Development Strategies and Applications for Bispecific Antibodies

The phenomenal growth of the bispecific antibody arena has culminated in 60 unique constructs, more than 30 in clinical development, and two on the market as therapeutics for a wide variety of cancer types and numerous diseases/disorders. Bispecific antibodies are specially engineered antibodies which simultaneously bind to two different epitopes on the same antigen or different antigens, increasing selectivity and effectiveness.

Creating New Pathways for the Development, Translation, and Delivery of Immunotherapies

The last decade has seen substantial growth of immunotherapy treatments for cancer. The new immunotherapies have produced exciting results in terms of response rates to treatment for certain cancers, such as melanoma, which have been refractory to treatment, once substantial metastasis has occurred. The US Food and Drug Administration (FDA) has approved several antibodies against immune checkpoint inhibitors based on the encouraging results in clinical trials. Other types of immune therapies are also being developed which may also be useful in the treatment of cancer.

The Leading Meeting for Bioconjugates and Next Generation Protein Therapeutics

2 Tracks
Dedicated to Bioconjugates and Next Generation Protein Therapeutics
Case Studies and New Data Presentations
Attendees from Pharmaceutical, Biotech, and Solution Providers
Years of growing into the favorite gathering place for world-renowned academic and industry visionaries.
Experts and Scientists presenting new data and case studies
3 Days
For maximum network and knowledge share with your peers

Sponsorship & Exhibition Opportunities

Showcase the adaptability of your products to leading scientists representing the upstream development and bioprocessing chain, spanning early stage discovery to early stage development.

For more information or to begin building your custom sponsorship package today, contact Patty Rose at (857) 504-6689 or